Improving the prognosis of pancreatic cancer:insights from epidemiology,genomic alterations,and therapeutic challenges

作     者：Zhichen Jiang Xiaohao Zheng Min Li Mingyang Liu Zhichen Jiang;Xiaohao Zheng;Min Li;Mingyang Liu

作者机构：State Key Laboratory of Molecular OncologyNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of General SurgeryDivision of Gastroenterology and PancreasZhejiang Provincial People's HospitalAffiliated People's HospitalHangzhou Medical CollegeHangzhou 310014China Department of Pancreatic and Gastric SurgeryNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of General SurgeryBeijing Friendship HospitalCapital Medical UniversityBeijing 100050China Department of MedicineThe University of Oklahoma Health Sciences CenterOklahoma CityOK 73104USA 

出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)

年 卷 期：2023年第17卷第6期

页      面：1135-1169页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China(No.82273452) 

主　　题：pancreatic cancer cancer screening single cell molecular alterations precancerous lesion therapy resistance 

摘      要：Pancreatic cancer,notorious for its late diagnosis and aggressive progression,poses a substantial challenge owing to scarce treatment *** review endeavors to furnish a holistic insight into pancreatic cancer,encompassing its epidemiology,genomic characterization,risk factors,diagnosis,therapeutic strategies,and treatment resistance *** delve into identifying risk factors,including genetic predisposition and environmental exposures,and explore recent research advancements in precursor lesions and molecular subtypes of pancreatic ***,we highlight the development and application of multi-omics approaches in pancreatic cancer research and discuss the latest combinations of pancreatic cancer biomarkers and their *** also dissect the primary mechanisms underlying treatment resistance in this malignancy,illustrating the latest therapeutic options and advancements in the ***,we accentuate the urgent demand for more extensive research to enhance the prognosis for pancreatic cancer patients.